Clinical trial readout dates for Nuvation Bio Inc. Class A, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$2.2B
Cash & investments$663M~16 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04
In progress, no date published
Phase 3Safusidenib
Grade 2 IDH1-mutant glioma
date not published
Trial Planned
Phase 2Safusidenib with vorasidenib
IDH1-mutant glioma
date not published
Trial Planned
Cash position
Nuvation Bio Inc. Class A reported $663M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $42M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates